We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medical Services Stock Q1 Earnings on May 10: CRL, XON, INCR
Read MoreHide Full Article
With the earnings season drawing to a close and the majority of the bigwigs having reported results we can conclude that the earnings picture was positive. As of May 5, 412 S&P 500 members that account for 85.7% of the index’s total market capitalization reported results. Earnings for these companies are up 14.2% year over year on 7.3% higher revenues. Of these, 73.3% beat earnings estimates and 67.7% beat revenue estimates resulting in a blended beat of 52.9%.
Although estimates for the current period have come down, the magnitude has lessened quite a bit as compared to the previous quarters. Results from about 18% of the S&P 500 members are still awaited.
Notably, Medical is one of those sectors which is expected to record growth in the positive territory. As of May 5, 79.6% companies in the Medical sector reported results, putting up a blended beat of 60.5% (the percentage of companies that have beaten both earnings and revenue estimates). Overall the sector has registered 5.9% earnings growth on 6.1% higher revenues.
With these factors in mind, let’s see what awaits these three medical services stocks that are slated to release their first-quarter 2017 results on May 10.
Headquartered in Wilmington, MA, Charles River Laboratories International, Inc. (CRL - Free Report) is an early-stage contract research organization. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions accelerate their research and drug development efforts. The company delivered earnings surprise in the trailing four quarters, with the average beat of 7.63%. The company currently carries a Zacks Rank #3 (Hold) and has an Earnings ESP of 0.00%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Although the rank is favorable, the company’s 0.00% ESP makes surprise prediction difficult. Nevertheless, a long-term expected earnings growth rate of 12.76% raises confidence in the stock. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Charles River Laboratories International, Inc. Price and EPS Surprise
Intrexon Corporation missed expectations thrice in the four trailing quarters and matched estimates once, with an average negative surprise of 12.37%. The company follows a business model under which it commercializes its technologies through exclusive channel collaborations (ECC), licensing agreements and joint ventures with collaborators that have market and product development expertise, as well as sales and marketing capabilities to better products and processes to market.
The company currently carries a Zacks Rank #3 and has an Earnings ESP of 0.00%. Although the rank is favorable, the company’s 0.00% ESP makes surprise prediction difficult. (Read more: Will Intrexon Pull Off a Surprise in Q1 Earnings?)
INC Research Holdings, Inc. (INCR - Free Report) is a global contract research organization providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The company has a decent track record so far having beaten expectations in two of the last four quarters and missed the same in one with an average positive surprise of 4.2%. However, the company’s Zacks Rank #3 and an Earnings ESP of 0.00% make surprise prediction difficult.
INC Research Holdings, Inc. Price and EPS Surprise
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Medical Services Stock Q1 Earnings on May 10: CRL, XON, INCR
With the earnings season drawing to a close and the majority of the bigwigs having reported results we can conclude that the earnings picture was positive. As of May 5, 412 S&P 500 members that account for 85.7% of the index’s total market capitalization reported results. Earnings for these companies are up 14.2% year over year on 7.3% higher revenues. Of these, 73.3% beat earnings estimates and 67.7% beat revenue estimates resulting in a blended beat of 52.9%.
Although estimates for the current period have come down, the magnitude has lessened quite a bit as compared to the previous quarters. Results from about 18% of the S&P 500 members are still awaited.
Notably, Medical is one of those sectors which is expected to record growth in the positive territory. As of May 5, 79.6% companies in the Medical sector reported results, putting up a blended beat of 60.5% (the percentage of companies that have beaten both earnings and revenue estimates). Overall the sector has registered 5.9% earnings growth on 6.1% higher revenues.
With these factors in mind, let’s see what awaits these three medical services stocks that are slated to release their first-quarter 2017 results on May 10.
Headquartered in Wilmington, MA, Charles River Laboratories International, Inc. (CRL - Free Report) is an early-stage contract research organization. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions accelerate their research and drug development efforts. The company delivered earnings surprise in the trailing four quarters, with the average beat of 7.63%. The company currently carries a Zacks Rank #3 (Hold) and has an Earnings ESP of 0.00%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Although the rank is favorable, the company’s 0.00% ESP makes surprise prediction difficult. Nevertheless, a long-term expected earnings growth rate of 12.76% raises confidence in the stock. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Charles River Laboratories International, Inc. Price and EPS Surprise
Charles River Laboratories International, Inc. Price and EPS Surprise | Charles River Laboratories International, Inc. Quote
Intrexon Corporation missed expectations thrice in the four trailing quarters and matched estimates once, with an average negative surprise of 12.37%. The company follows a business model under which it commercializes its technologies through exclusive channel collaborations (ECC), licensing agreements and joint ventures with collaborators that have market and product development expertise, as well as sales and marketing capabilities to better products and processes to market.
The company currently carries a Zacks Rank #3 and has an Earnings ESP of 0.00%. Although the rank is favorable, the company’s 0.00% ESP makes surprise prediction difficult. (Read more: Will Intrexon Pull Off a Surprise in Q1 Earnings?)
Intrexon Corporation Price and EPS Surprise
Intrexon Corporation Price and EPS Surprise | Intrexon Corporation Quote
INC Research Holdings, Inc. (INCR - Free Report) is a global contract research organization providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The company has a decent track record so far having beaten expectations in two of the last four quarters and missed the same in one with an average positive surprise of 4.2%. However, the company’s Zacks Rank #3 and an Earnings ESP of 0.00% make surprise prediction difficult.
INC Research Holdings, Inc. Price and EPS Surprise
INC Research Holdings, Inc. Price and EPS Surprise | INC Research Holdings, Inc. Quote
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>